Impact Of TP53 Gene Promoter Methylation On Chronic Lymphocytic Leukemia Pathogenesis And Progression

References

• Gaidano G, Foà R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012;122(10):3432–3438. doi:10.1172/JCI6410123023714
   PubMed Web of Science ®Google Scholar
• Ghia P, Ferreri AM, Caligaris-Cappio F. Chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2007;64(3):234–246. PMID: 17544290. doi:10.1016/j.critrevonc.2007.04.008.17544290
   PubMed Web of Science ®Google Scholar
• Ponzoni M, Doglioni C, Caligaris-Cappio F. Chronic lymphocytic leukemia: the pathologist’s view of lymph node microenvironment. Semin Diagn Pathol. 2011;28(2):161–166. doi:10.1146/annurev-pathol-020712-16395521842701
   PubMed Web of Science ®Google Scholar
• Damle RN, Calissano C, Chiorazzi N. Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol. 2010;23(1):33–45. doi:10.1016/j.beha.2010.02.00120620969
   PubMed Web of Science ®Google Scholar
• Campo E, Ghia P, Montserrat E, et al. Chronic lymphocytic leukaemia/small lymphocytic lymphoma In: Swerdlow SH, Campo E, Harris N, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed Lyon: International Agency for Research on Cancer; 2017:216–221.
   Google Scholar
• Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10:37–50. doi:10.1038/nrc276419956173
   PubMed Web of Science ®Google Scholar
• Zenz T, Gribben JG, Hallek M, Ohner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood. 2012;119:4101–4107. doi:10.1182/blood-2011-11-31242122394601
   PubMed Web of Science ®Google Scholar
• Lee CJ, Evans J, Kim K, Chae H, Kim S. Determining the effect of DNA methylation on gene expression in cancer cells. Methods Mol Biol. 2014;1101:161–178. PMID: 24233782. doi:10.1007/978-1-62703-721-1_924233782
   PubMedGoogle Scholar
• Cheedipudi S, Genolet O, Dobreva G. Epigenetic inheritance of cell fates during embryonic development. Front Genet. 2014;5:19. doi:10.3389/fgene.2014.0001924550937
   PubMed Web of Science ®Google Scholar
• Tang W, Ho S-M. Epigenetic reprogramming and imprinting in origins of disease. Rev Endocr Metab Disord. 2007;8(2):173–182. doi:10.1007/s11154-007-9042-417638084
   PubMed Web of Science ®Google Scholar
• Hagood J. Beyond the genome: epigenetic mechanisms in lung remodeling. Physiology (Bethesda). 2014;29(3):177–185. doi:10.1152/physiol.00048.201324789982
   PubMed Web of Science ®Google Scholar
• Ross SA, Milner J. Epigenetic modulation and cancer: effect of metabolic syndrome? Am J Clin Nutr. 2007;86(3):872S–877S. doi:10.1093/ajcn/86.3.872S
   Web of Science ®Google Scholar
• Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat Rev Genet. 2000;1:11–19. doi:10.1038/3504953311262868
   PubMed Web of Science ®Google Scholar
• Hube F, Reverdiau P, Iochmann S, Gruel Y. Improved PCR method for amplification of GC-rich DNA sequences. Mol Biotechnol. 2005;31:81–84. doi:10.1385/MB:31:1:08116118416
   PubMed Web of Science ®Google Scholar
• Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21:5427–5440. doi:10.1038/sj.onc.120560012154405
   PubMed Web of Science ®Google Scholar
• Wang L, Kwong Y, Wong K, et al. Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. J Transl Med. 2014;12:52 PMCID: PMC3941938; PMID: 24559316. doi:10.1186/1479-5876-12-52.24559316
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science. 1991;253(5015):49–53. PMID 1905840. doi:10.1126/science.1905840.1905840
   PubMed Web of Science ®Google Scholar
• Iranpur-Mubarakeh V, Esmailizadeh AK. Rapid extraction of high quality DNA from whole blood stored at 4 _C for long period; 2010 Available from: http://www.protocol-online.org/prot/Protocols/Rapid-Extraction-of-High-Quality-DNA-from-Whole-Blood-Stored-at-4-C-for-Long-Period-4175.html. Accessed 314, 2018.
   Google Scholar
• Kashmoola M, Eissa A, Al-Takay D, Al-Allawi N. Molecular characterization of G6PD deficient variants in Nineveh province, Northwestern Iraq. Indian J Hematol Blood Transfus. 2015;3:133–136. doi:10.1007/s12288-014-0368-2
   Web of Science ®Google Scholar
• Galm O, Herman J. Methylation-specific polymerase chain reaction. Methods Mol Med. 2005;113:279–291. PMID:15968111. doi:10.1385/1-59259-916-8:27915968111
   PubMedGoogle Scholar
• Jarzynski A, Papiernik K, Polz-Dacewicz M. Analysis of mutation and promoter methylation of TP53 gene in tumors of the head and neck. Curr Issues Pharm Med Sci. 2016;29(2):53–56. doi:10.1515/cipms-2016-0011
   Google Scholar
• Fernàndez V, Jares P, Salaverria I, et al. Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica. 2008;93(1):132–136. doi:10.3324/haematol.1169418166798
   PubMed Web of Science ®Google Scholar
• Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473–4479. doi:10.1200/JCO.2009.27.876220697090
   PubMed Web of Science ®Google Scholar
• Zenz T, Kröber A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112:3322–3329. doi:10.1182/blood-2008-04-15407018689542
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481–488. doi:10.1182/asheducation-2010.1.48121239840
   PubMed Web of Science ®Google Scholar
• Wang C, Wang X.The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia. Int J Clin Exp Pathol. 2013;6(7):1223–1229. ISSN:1936-2625/IJCEP1304037.23826404
   PubMed Web of Science ®Google Scholar
• Gaiti F, Chaligne R, Gu H, et al. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature. 2019;569:576–580. doi:10.1038/s41586-019-1198-z31092926
   PubMed Web of Science ®Google Scholar
• Hudson J, Shoaibi M, Maestro R, Carnero A, Hannon G, Beach D. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999;190(10):1375–1382. doi:10.1084/jem.190.10.137510562313
   PubMed Web of Science ®Google Scholar
• Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018;107(2):138–150. doi:10.1007/s12185-017-2364-429143282
   PubMed Web of Science ®Google Scholar